Amoxicillin is not a recommended treatment for gonorrhea in the United States or Europe as of 2026. The CDC's 2021 STI treatment guidelines removed oral amoxicillin and other oral beta-lactams from first-line therapy because Neisseria gonorrhoeae resistance now exceeds safe thresholds in most regions. The only FDA-approved, guideline-endorsed regimen is a single 500 mg intramuscular dose of ceftriaxone, given with 1 g of oral azithromycin only when chlamydia coinfection is not excluded. Amoxicillin retains a narrow niche: a 2010-era option for uncomplicated urogenital infection in pregnant patients with confirmed penicillin-susceptible isolates, which is now rare.
The Mechanism: Why a Penicillin That Once Worked Now Fails
Amoxicillin kills Neisseria gonorrhoeae by binding penicillin-binding proteins (PBPs), specifically PBP2, in the bacterial cell wall. This blocks peptidoglycan cross-linking and triggers autolysis. In 1980, a 3 g single oral dose of amoxicillin plus probenecid cured roughly 95 percent of uncomplicated urogenital gonorrhea. That number collapsed because the bacterium acquired two distinct resistance tools.
The first is the plasmid-borne TEM-1 beta-lactamase, which enzymatically hydrolyzes the amoxicillin beta-lactam ring before it reaches PBP2. The second is chromosomal: mutations in the penA gene alter PBP2's shape so the drug binds poorly even when beta-lactamase is absent. A 2011 study of isolates from Sydney found that more than 80 percent of gonococcal strains carried at least one penA mosaic allele reducing penicillin susceptibility. These two mechanisms stack: a strain with both beta-lactamase and a mosaic penA is effectively untreatable with any oral penicillin.
In plain terms: amoxicillin is a key, and the bacterium has both changed the lock and started secreting acid that dissolves the key before it arrives.
Quantified Context: How High Resistance Actually Is
Global surveillance numbers make the case bluntly. The WHO's 2018 Gonococcal Antimicrobial Surveillance Programme reported penicillin resistance in 30 to 100 percent of isolates across participating countries, with the highest rates in Southeast Asia and the Western Pacific. The U.S. Gonococcal Isolate Surveillance Project (GISP) tracked penicillin resistance fluctuating between 14 and 30 percent of isolates from 2010 to 2020, and beta-lactamase-producing strains at 8 to 15 percent. These figures are not marginal. A treatment that fails in one of every four patients is not a treatment.
| Regimen | Dose | Efficacy (urogenital) | Guideline status (2026) | Resistance concern |
|---|---|---|---|---|
| Amoxicillin | 3 g oral + 1 g probenecid | 85–95% (1980); under 70% today | Not recommended | High; beta-lactamase and PBP2 mutations |
| Ceftriaxone | 500 mg IM single dose | Greater than 99% | First-line | Low but monitored (ceftriaxone MIC creep) |
| Cefixime | 800 mg oral single dose | 95–97% | Alternative only if IM refused | Rising; not recommended as monotherapy |
| Azithromycin | 1 g oral single dose | 95% historically; declining | Adjunct only; not monotherapy | High and rising globally |
| Spectinomycin | 2 g IM single dose | 98% | Reserved; supply limited | Low |
The efficacy gap between amoxicillin (below 70 percent today) and ceftriaxone (above 99 percent) is the entire reason the guidelines changed. Per the CDC's 2021 STI Treatment Guidelines, ceftriaxone 500 mg IM is the sole first-line recommendation.
A Timeline: How Amoxicillin Fell From First-Line to Contraindicated
The decline was gradual and geographically uneven, which is why older clinicians still recall prescribing it.
| Period | Status of amoxicillin | Key event |
|---|---|---|
| 1970s–1980s | Standard oral therapy | 3 g amoxicillin + probenecid cured roughly 95% |
| 1986 | Still used widely | Penicillinase-producing strains reported in the U.S. |
| 1990s | Declining use | Widespread beta-lactamase plasmids; fluoroquinolones rise |
| 2010 | Narrow niche | Retained only for penicillin-susceptible isolates in pregnancy |
| 2015 | Largely abandoned | Rising ceftriaxone MICs dominate concern |
| 2021 | Removed from first-line | CDC STI guidelines drop oral beta-lactams |
| 2026 | Not recommended | Resistance exceeds clinical utility threshold |
Variations and Edge Cases Where Amoxicillin Lingers
Two real clinical situations still touch amoxicillin. The first is pregnancy. A 2019 review in Clinical Microbiology Reviews noted that for pregnant patients with documented penicillin-susceptible gonococcal isolates and a severe cephalosporin allergy, amoxicillin remains a theoretical option. That scenario is rare because penicillin-susceptible isolates now make up a small fraction of circulating strains and susceptibility testing is not routinely performed before empiric therapy.
The second is pharyngeal infection. Amoxicillin failed disproportionately at the pharynx even in the 1980s, achieving cure rates below 60 percent in some trials. The anatomical reason is that pharyngeal tissue has lower drug penetration and a different local immune environment. This is a non-obvious point: amoxicillin was never equally effective across body sites, even before widespread resistance. Urogenital cure rates were always higher than pharyngeal cure rates by 20 to 30 percentage points.
Common Misconceptions and the Coinfection Trap
The most dangerous misconception is that amoxicillin can be substituted if ceftriaxone is unavailable. It cannot. The second is that the patient's own amoxicillin leftover from a prior respiratory infection is a reasonable stopgap. That logic fails on two counts: the dose is wrong, and the resistance mechanism is already present.
A third misconception involves coinfection. Roughly 30 to 50 percent of patients with gonorrhea also have chlamydia, per CDC surveillance. Amoxicillin treats neither reliably; azithromycin or doxycycline is added for chlamydia, but neither substitutes for a gonorrhea-active agent. Anyone relying solely on amoxicillin is treating one target and missing another.
What to Actually Do
The practical actions are unambiguous. Get the right regimen the first time.
- Confirm the diagnosis with a nucleic acid amplification test (NAAT) before treating; gonorrhea symptoms overlap with chlamydia and trichomonas.
- Accept the intramuscular ceftriaxone 500 mg injection even if you dislike injections; oral alternatives are less effective.
- Take the full azithromycin 1 g if chlamydia has not been excluded; do not skip it because you feel better.
- Do not use leftover or borrowed amoxicillin under any circumstances.
- Screen and treat all sexual partners from the prior 60 days, per CDC guidance, to prevent reinfection.
- Return for a test-of-cure at 7 to 14 days if the pharynx was infected, because pharyngeal infection has higher treatment failure rates.
Limitations and the Resistance Trajectory
Ceftriaxone is not permanently safe either. GISP data show the ceftriaxone minimum inhibitory concentration (MIC) creeping upward, with isolates at 0.125 mg/L increasingly common. The 2021 guidelines reduced the ceftriaxone dose from 250 mg to 500 mg specifically to stay ahead of this drift. A 500 mg dose every treatment failure is a 5 to 10 percent loss of efficacy headroom.
The bigger limitation is that amoxicillin's failure is not reversible. Beta-lactamase plasmids are stable, and penA mosaic alleles are spreading through recombination among gonococcal lineages. Vaccines remain in early trials. In the absence of a vaccine, the only defense is accurate, high-dose ceftriaxone therapy and partner treatment. Any article promising that amoxicillin is "coming back" is misreading the resistance data.
The bottom line is binary. Amoxicillin for gonorrhea is obsolete outside a vanishing penicillin-susceptible niche, and the 500 mg intramuscular ceftriaxone dose is the standard that replaced it.